Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00203307 · ClinicalTrials.gov registry record · NA
A Research Study Examining the Use of Olanzapine for the Prevention of Migraine
A NA study, sponsored by Thomas Jefferson University.
- Terminated
- Registry status
- NA
- Development phase
- 3
- Enrollment target
NCT00203307: Clinical Trial NA study, sponsored by Thomas Jefferson University.
NCT00203307 is a NA study that was terminated before completion, run by Thomas Jefferson University. The registered enrollment target is 3 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00203307, a NA study, was terminated before completion, sponsored by Thomas Jefferson University.
- TERMINATED
- Registry status
- NA
- Development phase
- 3 participants
- Enrollment target
Study Summary
Olanzapine (o-lan-zah-peen) is a medication that has been approved by the Food and Drug Administration (FDA) for the treatment of patients with schizophrenia and/ or bipolar disorder. The trade name for this drug is Zyprexa®. Olanzapine has not been approved by the FDA for the prevention of migraine and is experimental for the purposes of this research study. The Jefferson Headache Center at Thomas Jefferson University has developed this clinical study to evaluate the safety and effectiveness of Olanzapine in preventing migraine headaches.
Primary Outcome
Definition of migraine headache period: One migraine period is defined as a 24-hour period starting at the time of onset of the migraine headache, during which the migraine headache is present\*. Definition of time frames: First treatment period: Day 1 to 84. Second treatment period: day 113-196. Washout phase is day 85-112.
Interventions
- DRUG Olanzapine during first intervention period and placebo during second intervention period
- DRUG Placebo during first intervention period, then olanzapine during second intervention period
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2004-05 |
| Est. Completion | 2006-06 |
| Phase | NA |
Why NCT00203307 stopped before completion
NCT00203307 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 2 interventions - of which Olanzapine during first intervention period and placebo during second intervention period is the first listed.
NCT00203307 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00203307 about?
NCT00203307 is a clinical study titled "A Research Study Examining the Use of Olanzapine for the Prevention of Migraine". Olanzapine (o-lan-zah-peen) is a medication that has been approved by the Food and Drug Administration (FDA) for the treatment of patients with schizophrenia and/ or bipolar disorder. The trade name for this drug is Zyprexa®. Olanzapine has not been approved by the FDA for the prevention of migraine...
What is the current status of trial NCT00203307?
This trial is currently terminated. It is a NA study. The enrollment target is 3 participants. The study started on 2004-05. Estimated completion is 2006-06.
What interventions are being tested in trial NCT00203307?
The interventions under investigation include: Olanzapine during first intervention period and placebo during second intervention period (DRUG), Placebo during first intervention period, then olanzapine during second intervention period (DRUG).
Who is sponsoring clinical trial NCT00203307?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00203307's enrollment target sits among peer trials
3 1996th of 2000 higher than 4 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia